The standard treatment for CRC is radical resection combined with adjuvant chemotherapy (Du et al., 2022), chemotherapy and radiotherapy is the standard of care for locally advanced disease, targeting Indoleamine 2,3 dioxygenase 1 (IDO1) can improve the effect of radiotherapy and slow down the growth of CRC tumors (Chen et al., 2020c). This evidence concerns the gene IDO1 and colorectal carcinoma.